NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Scala Biodesign

Scala Biodesign

Private
Tel AvivHealthcare & Life Scienceshttps://www.scala-bio.com/

Last Round

Series A

Mar 31, 2026

Total Funding Raised

$21.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Scala Biodesign is a biotechnology company that provides a computational platform using physics-based modeling, AI, and biological data analysis to engineer and design proteins for the pharmaceutical, chemical, and food industries.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting

AI Layer

Application

Keywords

protein designcomputational biologyin silico designbiologics developmentprotein engineeringdrug discoveryAI drug discoverybiotech AIantibody designenzyme engineeringphysics-based modelingprotein language modelsbiotech SaaSgenerative biologydigital biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Scala Biodesign Comps

Public and private peers based on sector, stage, and business model.

Scala Biodesign comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Scala Biodesign Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 31, 2026
SeedSep 11, 2023

Key People

Founding team and executive leadership

Adi Goldenzweig

Co-Founder CTO

Founding Team

Ravit Netzer

Co-founder And CEO

Founding Team

Scala Biodesign Investors

Notable investors and investment history

Scala Biodesign investors
InvestorRounds
Deep InsightSeries A
Israel Innovation AuthoritySeries A
Grove VenturesSeries A
TLV PartnersSeries A, Seed
Intel IgniteSeed
Ignite DeepTech AcceleratorSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 31, 2026

    Core technology developed at Weizmann Institute of Science.

  • Mar 31, 2026

    Developing ScalaOS, a platform for creating protein-based products.

Scala Biodesign Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Scala Biodesign Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Scala Biodesign's valuation, stock price, and market status.

Firmographic Details

HeadquartersTel Aviv
Employee Range30
Year Founded2022
Last FundingMar 31, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.